Aleš Žula

Aleš Žula

Auto-generated profile, based on publicly available information

Aleš Žula

Novartis, Global Drug Development, Technical Research & Development Biologics, Drug Product Development, Formulation Development Lek Pharmaceuticals d.d. Ljubljana , Slovenia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ŽHŽiga Hodnik
Žiga Hodnik
JŁJoanna M. Łoś
Joanna M. Łoś
AŽAleš Žula
Aleš Žula
NZNace Zidar
Nace Zidar
ŽJŽiga Jakopin
Žiga Jakopin
DKDanijel Kikelj
Danijel Kikelj

26 September 2022 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
MPMatic Proj
Matic Proj
MZMitja Zidar
Mitja Zidar
BLBlaž Lebar
Blaž Lebar
NSNika Strašek
Nika Strašek
GMGoran Miličić
Goran Miličić
SGStanislav Gobec
Stanislav Gobec
• Computational screening yielded 44 new viscosity-reducing agents on two model mAbs. • Dual excipients for viscosity reduction and solution buffering were discovered. • Compounds with three or more charges reduce the viscosity of model mAb formulations. • Filtering based on physicochemical properties can be applied to other mAb formulations.

1 September 2024 in Acta Pharmaceutica
Verified
Journal Article
Open access
BLBlaž Lebar
Blaž Lebar
MZMitja Zidar
Mitja Zidar
JMJanez Mravljak
Janez Mravljak
RŠRoman Šink
Roman Šink
AŽAleš Žula
Aleš Žula
SPStane Pajk
Stane Pajk
The formulation of biopharmaceutical drugs is designed to eliminate chemical instabilities, increase conformational and colloidal stability of proteins, and optimize interfacial stability. Among the various excipients involved, buffer composition plays a pivotal role. However, conventional buffers like histidine and phosphate buffers may not always be the optimal choice for all monoclonal antibodies (mAbs). In this study, we investigated the effects of several alternative buffer systems on seven different mAbs, exploring various combinations of ionic strengths, concentrations of the main buffer component, mAb concentrations, and stress conditions. Protein stability was assessed by analyzing soluble aggregate formation through size exclusion chromatography. At low protein concentrations, protein instability after temperature stress was exclusively observed in the bis-TRIS/ glucuronate buffer. Conversely, freeze-thaw stress led to a significant increase in aggregate formation in tested formulations, highlighting the efficacy of several alternative buffers, particularly arginine/ citrate, in preserving protein stability. Under temperature stress, the introduction of arginine to histidine buffer systems provided additional stabilization, while the addition of lysine resulted in protein destabilization. Similarly, the incorporation of arginine into histi-dine/HCl buffer further enhanced protein stability during freeze--thaw cycles. At high protein concentrations, the histidine/citrate buffer emerged as one of the most optimal choices for addressing temperature and light-induced stress. The efficacy of histidine buffers in combating light stress might be attributed to the light-absorbing properties of histidine molecules. Our findings demonstrate that the development of biopharmaceutical formulations should not be confined to conventional buffer systems, as numerous alternative options exhibit comparable or even superior performance.